Carina M Mathey, Carlo Maj, Niclas Eriksson, Kristi Krebs, Julia Westmeier, Friederike S David, Maria Koromina, Annika B Scheer, Nora Szabo, Bettina Wedi, Dorothea Wieczorek, Philipp M Amann, Harald Löffler, Lukas Koch, Clemens Schöffl, Heinrich Dickel, Nomun Ganjuur, Thorsten Hornung, Timo Buhl, Jens Greve, Gerda Wurpts, Emel Aygören-Pürsün, Michael Steffens, Stefan Herms, Stefanie Heilmann-Heimbach, Per Hoffmann, Börge Schmidt, Laven Mavarani, Trine Andresen, Signe Bek Sørensen, Vibeke Andersen, Ulla Vogel, Mikael Landén, Cynthia M Bulik, Anette Bygum, Patrik K E Magnusson, Christian von Buchwald, Pär Hallberg, Sisse Rye Ostrowski, Erik Sørensen, Ole B Pedersen, Henrik Ullum, Christian Erikstrup, Henning Bundgaard, Lili Milani, Eva Rye Rasmussen, Mia Wadelius, Jonas Ghouse, Bernhardt Sachs, Markus M Nöthen, Andreas J Forstner
BACKGROUND: Angioedema is a rare but potentially life-threatening adverse drug reaction in patients receiving angiotensin-converting enzyme inhibitors (ACEis). Research suggests that susceptibility to ACEi-induced angioedema (ACEi-AE) involves both genetic and nongenetic risk factors. Genome- and exome-wide studies of ACEi-AE have identified the first genetic risk loci. However, understanding of the underlying pathophysiology remains limited. OBJECTIVE: We sought to identify further genetic factors of ACEi-AE to eventually gain a deeper understanding of its pathophysiology...
January 22, 2024: Journal of Allergy and Clinical Immunology